Evaluation of the humoral response of glioma patients to a possible common tumor-associated antigen(s).
Cytotoxic antibodies against glioblastoma-associated antigen(s) have been sought for in glioma patient sera. Complement-dependent cytotoxicity (CDC) I and antibody-dependent cell-mediated cytotoxicity (ADCC) assays were used to test sera from 80 patients using 51 Cr labelled target cells derived from eight different glioblastoma lines. As more positive sera were detected with ADCC than with CDC, ADCC assay was used for the remainder of the study. Cytotoxic antibodies were detected in the sera from 8 of 80 glioma patients (10%) by CDC and in 20 of 143 (14%) by ADCC. Fourteen percent of 27 meningioma patients and 16% of 25 normal donors used as controls were found to react in ADCC against the same glioblastoma cell lines. The positive serum samples showed extensive cross-reactions with the different glioblastoma cells, but the pattern of reactivity was different for each serum tested. The antibodies detected did not seem to be directed against tumor-associated antigen(s), since the positive sera were found to have a similar ADCC reactivity against unrelated tumor cells and normal fibroblasts. Moreover, their antiglioma reactivity was absorbed by cells of unrelated tumors and by normal platelets. These results do not support previous reports of specific humoral responses in glioma patients against common tumor-associated antigen(s).
D000042:Absorption; D000917:Antibody Formation; D000920:Antibody-Dependent Cell Cytotoxicity; D000951:Antigens, Neoplasm / Q000276:immunology*; D001932:Brain Neoplasms / Q000276:immunology*; D002460:Cell Line; D003165:Complement System Proteins / Q000276:immunology; D003601:Cytotoxicity Tests, Immunologic; D005910:Glioma / Q000276:immunology*; D006801:Humans; D013997:Time Factors
D000951:Antigens, Neoplasm; D003165:Complement System Proteins